Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Straumann Holding 2025: Strong Growth, Innovation & 2026 Outlook in Dental Implants

Straumann Holding AG reports 2025 earnings growth, expanding implant pipeline, and a focus on sustainability and supply‑chain resilience, while navigating Asia‑Pacific demand constraints.

Dr. Sarah Winters

20/02/2026, 18:20

3 minutes to read

Insulet Q4 2024 Earnings Beat, Omnipod Sales Drive 31% Revenue Surge

Insulet’s Q4 2024 earnings beat estimates, with a 31% revenue lift from Omnipod sales, expanding margins and a share‑repurchase program driving a 7% stock gain.

Dr. Sarah Winters

20/02/2026, 17:21

4 minutes to read

How Bayer’s Roundup Settlement, Credit Downgrade and Market Shifts Shape Its Future

Explore how Bayer AG’s Roundup settlement, Fitch downgrade, and market shifts risk its future pharma and ag‑chem success.

Dr. Sarah Winters

20/02/2026, 12:52

4 minutes to read

Fresenius Medical Care: Stable Shares Reflect Market Trends, Not New Catalysts

Fresenius Medical Care AG remains a stable dialysis leader, with shares reflecting market trends rather than new earnings or regulatory moves.

Dr. Sarah Winters

20/02/2026, 10:33

2 minutes to read

Danaher’s $9.9 B Takeover of Masimo: Boosting Acute‑Care Diagnostics & Innovation

Danaher’s $9.9 B acquisition of Masimo will boost acute‑care diagnostics, unlock $200‑$300 M synergies, and accelerate AI‑driven monitoring innovation.

Dr. Sarah Winters

20/02/2026, 09:43

4 minutes to read

Straumann Holding 2025 Results: Strong Revenue, EPS Growth, & Strategic Expansion

Straumann Holding AG posts 2025 growth: CHF 2.6 b revenue, CHF 3.0 EPS, and a strong 15.4 % margin, driven by digital‑dentistry innovation, global expansion and robust cash flow, positioning for 2026 success.

Dr. Sarah Winters

20/02/2026, 07:34

3 minutes to read

Sanofi’s Duvakitug Shows 78% UC Remission in LTE: Boosting IBD Pipeline & New SCBU Leadership

Sanofi’s LTE data show duvakitug achieves 78 % remission in UC and 73 % in CD with acceptable safety, while new SCBU leadership aims to boost specialty growth and R&D investment.

Dr. Sarah Winters

20/02/2026, 05:15

3 minutes to read

FDA Grants Expanded Approval for Sandoz’s Enzeevu, Broadening Biosimilar Use in RVO, DR, and DME

FDA approves Sandoz’s Enzeevu for RVO, DR, and DME: clinical efficacy matches Eylea, offers cost‑effective, expanded retinal treatment.

Dr. Sarah Winters

20/02/2026, 04:03

4 minutes to read

Dexcom’s Earnings Miss Sparks Short‑Term Drop, Long‑Term Outlook Stays Bullish

Dexcom’s stock dipped after earnings miss, but its superior CGM technology, growing diabetes market, and strong future pipeline keep it a bullish long‑term play.

Dr. Sarah Winters

20/02/2026, 00:23

4 minutes to read

Humana Stock Rebounds: Strong P/E, Medicare Advantage Focus, and Investor Confidence

Humana’s recent stock rebound, stable P/E, and focus on coordinated care and provider stability in Medicare Advantage signal resilience and growth potential for investors, clinicians, and patients alike.

Dr. Sarah Winters

19/02/2026, 22:53

2 minutes to read

Older articles